CD160 and breast carcinoma: Indeed, in our study, genetically elevated circulating protein levels of CD160 are associated with a protective effect in breast cancer, suggesting that a drug activating CD160 specifically on NK cells may enhance anti-tumour immune responses in breast cancer.